Designed to push the boundaries of medical innovation, we're running #clinicaltrials committed to advancing cutting-edge research in some of the world's most debilitating diseases For more information visit: #ClinicalTrialsDay #CTD2024

Happy Independence Day from Biohaven! Wishing all a relaxing and safe holiday. #FourthOfJuly #IndependenceDay 🇺🇸

Events like the Annual SMA Conference continue to emphasize to our team that patients and families are counting on us. We are leaving this @CureSMA #conference feeling more inspired than ever to help people living with #SMA. #spinalmuscularatrophy

In a guest column in @_CellandGene, Melissa Beiner, MD, our Senior Medical Director, highlights the physical, emotional and socioeconomic impact of spinocerebellar ataxia (SCA), emphasizing the need for greater awareness, research and regulatory support:

Check out our feature in @AtaxiaUK’s magazine after a visit to their London office. In a Q&A, our Rare Disease Marketing, Patient Advocacy and Engagement Lead shares how meeting the #SCA community deepens our purpose and drives our research forward:

Our Executive Medical Director, Bharat Awsare, MD, shares his view on precision medicine’s future in @PharmExec highlighting a shift to targeting root causes, not just symptoms. Read more: #PrecisionMedicine

We’re teaming up with Bexorg Inc., using their human brain and #AI system to advance how we study neuro treatments. Featured in @endpointsnews, this approach helps us better assess drug activity and biomarkers earlier in development. Read more:

At #AAN2025, Volkan Granit, MD, MSc, our Medical Director of Clinical Development, sat down with @VJNeurology to discuss our investigational TRPM3 antagonist and its potential role in treating pain. View the full interview: .#PainResearch #DaysMatter.

We’ve enrolled the first patient in our Phase 2/3 #clinicaltrial of a first-in-class, oral, brain-penetrant TYK2/JAK1 inhibitor for early #ParkinsonsDisease. This novel therapy targets neuroinflammation and immune dysregulation driving disease progression:

Congrats to Gene Dubowchik, Ph.D., our SVP of Molecular Technologies, on being elected to the CT Academy of Science and Engineering! This honor highlights Gene’s leadership and lasting impact on science and innovation in Connecticut. #CASE2025 #STEM

We shared early clinical data at our Research and Development Day showing encouraging results from our next-generation #ADC programs. Our first-in-class FGFR3-directed ADC has also entered the clinic: #MedEd #MedX.

Professor @IgAN_JBarratt from @uniofleicester shares why he’s excited about our extracellular #degrader technology and its potential to transform treatment for IgA nephropathy by targeting the root cause while sparing the rest of the #immune system. #IgANephropathy #MedEd

We are joining the @Yale_Ventures Innovation Summit, featuring 40+ panels across #biotech, #health, #neuroscience and more. A global gathering of leaders and entrepreneurs shaping the future. Registration is now open: #YaleInnovation25

#ICYMI: At the @AANmember Annual Meeting, Jason Lerner, MD, sat down with @VJNeurology to talk about our investigational potassium channel activator being studied for #epilepsy and #neuropsychiatricdisorders. Learn more about our study results:

We’re joining @NAF_Ataxia in urging the FDA to take action for people living with #spinocerebellarataxia (SCA) and other rare diseases still waiting for approved therapies. This petition is a call for urgency, compassion, and change: #DaysMatter.

Biohaven is going green for #MentalHealthAwarenessMonth. We stand with everyone affected by #mentalhealth challenges and are proud to raise awareness and show our support. #DaysMatter #MajorDepressiveDisorder #OCD

Honored to learn from leading #physicians and #scientists at our recent peripartum cardiomyopathy ad board. Their insights are shaping Biohaven’s efforts to improve #cardiac outcomes for new moms. We also presented at @CPPCongress last week. Learn more:

Exciting news: Biohaven has secured up to $600M in strategic #investment from Oberland Capital. This financing strengthens our mission to deliver life-changing therapies across immunology, neuroscience, and oncology. Learn more: #InvestorNews $BHVN

Our team has wrapped up another successful @AANMember Annual Meeting. A huge thank you to everyone who participated and shared their insights. Check out some highlights from the event! #AAN2025 #SCA #Epilepsy #Migraine #Parkinsons

In the latest episode of Global Genes RARECast, our Senior Medical Director, Melissa Beiner, M.D., talks about #spinocerebellarataxia (SCA), a rare and progressive disease that impacts movement, balance and coordination: #CareAboutRARE #RareDisease

We’re heading to the @AANMember Annual Meeting to connect with leading experts share the latest research and discuss advancements in #neurology. If you're attending #AAN2025, be sure to stop by: #SCA #Epilepsy #Migraine #Parkinsons